More on TRUFF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.02 |
|
|||
| Open | $0.02 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.02 | ||||
| Day Low | $0.02 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 297,259 | ||||
- Rhelion unit expands psilocybin supply deal for Italian clinical trial
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
- Filament Health ships psilocybin drug to Phase 3 palliative care trial
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
- Rhelion unit signs psilocybin supply deal with Dutch research center
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
- Rhelion unit signs USC supply deal for psilocybin drug candidate
- Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Entities mentioned with TRUFF
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Bitcoin | View Related Stories »
- Twitter | View Related Stories »
- Show More...
